Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Non-Current Debt: 2021

  • ARS Pharmaceuticals' Non-Current Debt was N/A to $4.9 million in Q4 2021 from the same period last year, while for Dec 2021 it was $4.9 million, marking a year-over-year change of. This contributed to the annual value of $4.9 million for FY2021, which is N/A change from last year.
  • As of Q4 2021, ARS Pharmaceuticals' Non-Current Debt stood at $4.9 million.
  • In the past 5 years, ARS Pharmaceuticals' Non-Current Debt registered a high of $4.9 million during Q4 2021, and its lowest value of $4.9 million during Q4 2021.
  • Over the past 1 years, ARS Pharmaceuticals' median Non-Current Debt value was $4.9 million (recorded in 2021), while the average stood at $4.9 million.